Closed Clinical Trials
Here you will find a list of all of the current Closed Clinical Trials that we are running within the Stroke Research Team. Should you wish to find out any more pieces of information about the trials, please send an email and we will answer your query.
| Trial short title |
CROMIS-2 |
| Trial long title |
Microbleeds and genetic risk factors to predict the risk of intracranial haemorrhage in tatients treated with anticoagulation following cardioembolic stroke due to atrial fibrillation |
| Trial outcome |
To develop a successful predictive model for ICH risk after best practice oral anticoagulation for AF will help to determine whether genetic or CMB screening should be used in clinical practice and future trials. New genetic, clinical and radiological risk factors associated with anticoagulant-related ICH will be identified. |
| Chief investigator |
Dr. David Werring |
| Principle investigator |
Dr. John Bamford |
| Start date |
27/02/2012 |
| End date |
31/10/2017 |
| Project type |
Non-Commercial |
| Trial short title |
ENCHANTED |
| Trial long title |
Enhanced control of hypertension and thrombolysis stroke study |
| Trial outcome |
This study is an international, multicentre, prospective, fixed-time point (optional) randomisation for two arms ([A] ‘dose of rtPA’ and [B] ‘level of BP control’), open, blinded endpoint (PROBE), controlled trial that will involve 4800 patients (3300 for arm [A] and 2304 for arm [B] with overlap of approximately 800 patients) with acute ischaemic stroke recruited from over 100+ Clinical Centres from Australia, Asia, Europe and South America. |
| Chief investigator |
Prof. Craig Anderson |
| Principle investigator |
Dr. Ahamad Hassan |
| Start date |
08/06/2012 |
| End date |
31/08/2018 |
| Project type |
Non-Commercial |
| Trial short title |
EXTRAS |
| Trial long title |
A trial to evaluate an extended rehabilitation service for stroke patients |
| Trial outcome |
The EXTRAS trial aims to determine the clinical and cost effectiveness of an extended stroke rehabilitation service. Stroke patients and carers who agree to participate in the trial are randomly allocated to either receive a new extended stroke rehabilitation service or to continue with usual NHS care. The effectiveness of the new extended rehabilitation service will be evaluated by comparing the health of patients and carers who received the new service with those who received usual NHS care. |
| Chief investigator |
Prof. Helen Rodgers |
| Principle investigator |
Dr. John Bamford |
| Start date |
05/11/2012 |
| End date |
30/06/2015 |
| Project type |
Non-Commercial |
| Trial short title |
FOCUS |
| Trial long title |
Fluoxetine or control under supervision |
| Trial outcome |
Does the routine administration of fluoxetine (20mg od) for 6 months after an acute stroke improve patients’ functional outcome? |
| Chief investigator |
Prof. Martin Dennis and Prof. Gillian Mead |
| Principle investigator |
Dr. John Bamford |
| Start date |
01/04/2012 |
| End date |
01/06/2016 |
| Project type |
Non-Commercial |
| Trial short title |
PISTE |
| Trial long title |
Pragmatic Ischaemic Stroke Thrombectomy Evaluation |
| Trial outcome |
To determine if endovascular thrombectomy in addition to IV thrombolysis improves the proportion of patients with favourable functional 3 month outcome (defined by modified Rankin 0-2) in patients with acute ischaemic stroke due to occlusion of the middle cerebral or intracranial internal carotid artery |
| Chief investigator |
Prof. Keith Muir |
| Principle investigator |
Dr. John Bamford |
| Start date |
02/04/2013 |
| End date |
28/04/2015 |
| Project type |
Non-Commercial |
| Trial short title |
PRESERVE |
| Trial long title |
How intensively should we treat blood pressure in established cerebral small vessel disease |
| Trial outcome |
To determine whether a strategy of intensive, verses standard, treatment of BP in hypertensive individuals with SVD and leukoaraiosis is associated with reduced cognitive decline |
| Chief investigator |
Prof. Hugh Markus |
| Principle investigator |
Dr. Ahamad Hassan |
| Start date |
14/10/2011 |
| End date |
02/11/2015 |
| Project type |
Non-Commercial |
| Trial short title |
STRO 3595 NAVIGATE ESUS |
| Trial long title |
Multicenter, randomized, double-blind, double-dummy, active-comparator, event-driven, superiority phase III study of secondary prevention of stroke and prevention of systemic embolism in patients with a recent Embolic Stroke of Undetermined Source (ESUS), comparing rivaroxaban 15 mg once daily with aspirin 100 mg (NAVIGATE ESUS) |
| Trial outcome |
The NAVIGATE ESUS research study is seeking a safe and more effective alternative to aspirin treatment to prevent another stroke in patients who already suffered a stroke of uncertain cause. “ESUS” stands for Embolic Stroke of Undetermined Source. |
| Chief investigator |
Robert G. Hart M.D and Stuart J. Connolly M.D |
| Principle investigator |
Dr. Vasileios Papavasileiou |
| Start date |
23/12/2014 |
| End date |
15/02/2018 |
| Project type |
Commercial |
| Trial short title |
TARDIS |
| Trial long title |
Triple Antiplatelets for Reducing Dependency after Ischaemic Stroke |
| Trial outcome |
Safety and efficacy of intensive versus guideline antiplatelet therapy in high risk patients with recent ischaemic stroke or transient ischaemic attack: a randomised controlled trial |
| Chief investigator |
Prof. Philip Bath |
| Principle investigator |
Dr. John Bamford |
| Start date |
07/04/2009 |
| End date |
13/04/2016 |
| Project type |
Non-Commercial |
| Trial short title |
TICH-2 |
| Trial long title |
Tranexamic acid for hyperacute primary intracerebral haemorrhage |
| Trial outcome |
To assess whether tranexamic acid is safe and reduces death and dependency after hyperactute (within 8 hours of onset) primary intracerebral haemorrhage |
| Chief investigator |
Dr. Nikola Sprigg |
| Principle investigator |
Dr. Sameer Limaye |
| Start date |
01/03/2013 |
| End date |
31/07/2017 |
| Project type |
Non-Commercial |
| Trial short title |
VIST |
| Trial long title |
Vertebral artery ischaemic stenting trial |
| Trial outcome |
A multicentre randomised controlled open prospective clinical trial comparing vertebral stenting with best medical treatment |
| Chief investigator |
Prof. Hugh Markus |
| Principle investigator |
Dr. Ahamad Hassan |
| Start date |
23/10/2008 |
| End date |
09/02/2015 |
| Project type |
Non-Commercial |
To return to the top, please click here
